Trump Drug Mystery

STAT reported that Eli Lilly and the FDA granted a single 79-year-old man access to retatrutide, an experimental obesity drug, through the federal “compassionate use” program, prompting questions about whether the patient was President Donald Trump. The application reportedly came from an NIH clinician and described “refractory obesity” with obstructive sleep apnea and pulmonary hypertension, conditions that drew interest from senior health officials because retatrutide remains unapproved and potentially far more potent than current GLP-1 drugs. Trump, who recently turned 80, has long faced scrutiny over limited White House disclosures about his health, and the patient’s age and apparent government connections fueled speculation that presidential influence may have been involved. The report has turned a narrow regulatory decision into a broader political and medical controversy over transparency, access and the president’s health.